Literature DB >> 15257950

Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.

Amparo Santamaría, Antonio Martínez-Rubio, Montserrat Borrell, José Mateo, Rosa Ortín, Jordi Fontcuberta.   

Abstract

To our knowledge, there is little information about functional thrombin activatable fibrinolysis inhibitor (TAFI) levels and the risk of acute coronary artery disease (CAD). We investigated the risk of acute CAD related to plasma levels of functional TAFI. We found that functional TAFI levels in plasma (above 126%), increased the risk of acute CAD almost 4-fold.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15257950

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  14 in total

1.  Genome association study of human chromosome 13 and susceptibility to coronary artery disease in a Chinese population.

Authors:  Peng Jie; Chen Xing; Li Tingting; Xie Yi; Zhang Jianning; Jiang Tingting; Liu Tianjiao; Chen Gang; Guo Yuan
Journal:  J Genet       Date:  2013-04       Impact factor: 1.166

2.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

3.  Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Authors:  Masahiro Ieko; Mika Yoshida; Sumiyoshi Naito; Toru Nakabayashi; Kaoru Kanazawa; Kazuhiro Mizukami; Masaya Mukai; Tatsuya Atsumi; Takao Koike
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

4.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

5.  Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.

Authors:  Mirjam E Meltzer; Carine J M Doggen; Philip G de Groot; Joost C M Meijers; Frits R Rosendaal; Ton Lisman
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

6.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; İrfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

7.  Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.

Authors:  M N Yildirim; Y Selcoki; S Uysal; A B Nacar; B Demircelik; H I Aydin; B Eryonucu
Journal:  Herz       Date:  2013-09-27       Impact factor: 1.443

8.  Impaired fibrinolysis in angiographically documented coronary artery disease.

Authors:  Adriano Basques Fernandes; Luciana Moreira Lima; Marinez Oliveira Sousa; Vicente de Paulo Coelho Toledo; Rashid Saeed Kazmi; Bashir Abdulgader Lwaleed; Maria das Graças Carvalho
Journal:  Adv Hematol       Date:  2015-02-23

9.  Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.

Authors:  You Li; Zhiliang Zeng; Jianghao Zhao; Guoda Ma; Lili Cui; Hua Tao; Zhijun Lin; Yanyan Chen; Bin Zhao; Yusen Chen; Keshen Li
Journal:  Lipids Health Dis       Date:  2014-05-13       Impact factor: 3.876

10.  Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study.

Authors:  Huixu Dai; Jingpu Shi; Qiao He; Hao Sun
Journal:  Med Sci Monit       Date:  2017-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.